Last reviewed · How we verify
INOTERSEN
INOTERSEN is a drug. It is currently FDA-approved.
At a glance
| Generic name | INOTERSEN |
|---|---|
| Modality | Oligonucleotide |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
- ION-682884 in Patients With TTR Amyloid Cardiomyopathy (PHASE2)
- 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients (PHASE2)
- TEGSEDI Pregnancy Surveillance Program
- A Study to Characterize Adverse Events Occurring Within One Day of TEGSEDI Administration to Adult Participants With hATTR-PN (PHASE4)
- NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (PHASE3)
- Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP) (PHASE3)
- ATTR Expanded Access Program (EAP) by Ionis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INOTERSEN CI brief — competitive landscape report
- INOTERSEN updates RSS · CI watch RSS
Frequently asked questions about INOTERSEN
What is INOTERSEN?
INOTERSEN is a Oligonucleotide drug.
What development phase is INOTERSEN in?
INOTERSEN is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing